UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000024229
Receipt No. R000027816
Scientific Title Effects of a Granule Containing Fermented Soba Extract (neo-FBS) on the Decrease of Blood Pressure
Date of disclosure of the study information 2016/10/01
Last modified on 2017/04/03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Effects of a Granule Containing Fermented Soba Extract (neo-FBS) on the Decrease of Blood Pressure
Acronym Effects of a Granule Containing Fermented Soba Extract (neo-FBS) on the Decrease of Blood Pressure
Scientific Title Effects of a Granule Containing Fermented Soba Extract (neo-FBS) on the Decrease of Blood Pressure
Scientific Title:Acronym Effects of a Granule Containing Fermented Soba Extract (neo-FBS) on the Decrease of Blood Pressure
Region
Japan

Condition
Condition Normal high blood pressure or Grade 1 hypertension
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 This study examine effect of a granule containing fermented soba extract (neo-FBS) on the decrease of blood pressure.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Blood pressure, pulsation (Week 0, Week 4, Week 8, Week 12)
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 3
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 Oral ingestion of the test products containing fermented soba extract (2g per a day; 8 weeks)
Interventions/Control_2 Oral ingestion of the test products containing fermented soba extract (2g per a day; 8 weeks)
Interventions/Control_3 Oral ingestion of the placebo not containing fermented soba extract (2g per a day; 8 weeks)
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
30 years-old <=
Age-upper limit
70 years-old >
Gender Male and Female
Key inclusion criteria 1) Males and females aged 30-70 years
2) Individuals who are healthy and are not receiving treatment of disease
3) Individuals who are high normal blood pressure (SBP: 130-140mmHg and/or DBP: 85-90mmHg) and Grade 1 hypertension (SBP: 140-160mmHg and/or DBP: 90-100mmHg)
4) Individuals whose written informed consent has been obtained
5) Individuals judged appropriate for the study by the principal
Key exclusion criteria 1) Individuals who are sensitive to a food containing soba and test product or other foods, and medical products
2) Individuals who are receiving treatment of serious hepatopathy, kidney damage, heart disease and hematological disease
3) Individuals who have a habit of smoking
4) Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements in the past 3 months or will ingest those foods during the test period
5) Individuals who participated in other clinical studies in the past three months
6) Individuals who are or are possibly pregnant, or are lactating
Target sample size 54

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Toru Sahashi
Organization SBS Shizuoka Health Promotion Center
Division name Deputy Director
Zip code
Address 3-1-1, Toro Shizuoka Suruga-ku, Shizuoka
TEL 054-282-1109
Email dokku@sbs-smc.or.jp

Public contact
Name of contact person
1st name
Middle name
Last name Masanori Inoue
Organization Laboratory of Cell Applied Technologies, Co
Division name Director
Zip code
Address 2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8512 Japan
TEL 044-979-1622
Homepage URL
Email info@l-cat.co.jp

Sponsor
Institute Laboratory of Cell Applied Technologies, Co
Institute
Department

Funding Source
Organization Daiwa Pharmaceutical Co.,Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 10 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2016 Year 09 Month 04 Day
Date of IRB
Anticipated trial start date
2016 Year 10 Month 22 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 09 Month 30 Day
Last modified on
2017 Year 04 Month 03 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027816

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.